[The US Senate questioned that the "weight-loss wonder drug" was overpriced. Novo and Nordisk responded that it was useless to cut the price.] On Tuesday (September 24), the CEO of Danish pharmaceutical giant Novo Nordisk Lars Jorgensen accepted a question in the US Senate. The senators believed that the obesity reducing drug Wegovy and the diabetes drug Ozempic of Novo Nordisk were overpriced in the US, significantly higher than their prices in Europe.